Several analysts have recently updated their ratings and price targets for Inovio Pharmaceuticals (NASDAQ: INO): 5/23/2022 – Inovio Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating. 5/11/2022 – Inovio Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating. 5/11/2022 – Inovio Pharmaceuticals had […]
Related Keywords
University Of Pennsylvania ,Pennsylvania ,United States ,Blue Bell ,Canada , ,University Of Southampton ,Zacks Investment Research ,Inovio Pharmaceuticals Inc ,Parametric Portfolio Associates ,Nasdaq ,Oppenheimer Holdings Inc ,Kokusai Asset Management Co ,Cantor Fitzgerald ,Vaccines Trial Network ,Proshare Advisors ,Inovio Pharmaceuticals ,Inovio Biomedical Corporation ,Mitsubishi Ufj ,Oppenheimer Holdings ,National Microbiology Laboratory ,Public Health Agency ,Get Rating ,Share Advisors ,Portfolio Associates ,Asset Management ,Nasdaq Ino ,Ino ,
vimarsana.com © 2020. All Rights Reserved.